Invesco Ltd. Has $1.24 Million Holdings in Novavax, Inc. (NASDAQ:NVAX)

Invesco Ltd. lessened its stake in shares of Novavax, Inc. (NASDAQ:NVAX - Free Report) by 82.9% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 154,425 shares of the biopharmaceutical company's stock after selling 750,742 shares during the period. Invesco Ltd. owned 0.10% of Novavax worth $1,242,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. E Fund Management Co. Ltd. increased its position in shares of Novavax by 5.1% during the fourth quarter. E Fund Management Co. Ltd. now owns 25,340 shares of the biopharmaceutical company's stock valued at $204,000 after acquiring an additional 1,219 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in Novavax by 0.4% in the fourth quarter. Bank of New York Mellon Corp now owns 436,451 shares of the biopharmaceutical company's stock valued at $3,509,000 after acquiring an additional 1,664 shares in the last quarter. Federated Hermes Inc. grew its stake in shares of Novavax by 4.4% during the fourth quarter. Federated Hermes Inc. now owns 50,506 shares of the biopharmaceutical company's stock worth $406,000 after purchasing an additional 2,124 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its position in shares of Novavax by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 33,965 shares of the biopharmaceutical company's stock worth $273,000 after acquiring an additional 3,174 shares in the last quarter. Finally, Commonwealth Equity Services LLC increased its stake in Novavax by 8.1% in the fourth quarter. Commonwealth Equity Services LLC now owns 43,034 shares of the biopharmaceutical company's stock valued at $346,000 after purchasing an additional 3,236 shares during the last quarter. 53.04% of the stock is currently owned by institutional investors and hedge funds.

Novavax Stock Performance

NASDAQ NVAX remained flat at $6.41 during trading hours on Friday. 3,628,219 shares of the company's stock were exchanged, compared to its average volume of 8,383,053. Novavax, Inc. has a 1 year low of $4.43 and a 1 year high of $23.86. The company has a market cap of $1.03 billion, a PE ratio of -2.84, a PEG ratio of 2.85 and a beta of 3.15. The company has a 50 day moving average of $7.01 and a 200-day moving average of $8.16.

Novavax (NASDAQ:NVAX - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.24. The business had revenue of $88.31 million during the quarter, compared to the consensus estimate of $85.48 million. During the same period in the previous year, the company posted ($1.44) EPS. As a group, sell-side analysts forecast that Novavax, Inc. will post -1.46 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

NVAX has been the subject of several research reports. BTIG Research initiated coverage on shares of Novavax in a research report on Friday, February 28th. They issued a "buy" rating and a $19.00 price target for the company. TD Cowen upgraded Novavax to a "hold" rating in a research report on Thursday, February 27th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $18.00.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.